Revenue segments as reported by the company.

Life Sciences and Applied Markets Group

Diagnostics and Genomics Group

Agilent CrossLab Group

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Agilent Technologies

Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. The Diagnostics and Genomics segment consists of activity providing active pharmaceutical ingredients for oligo-based therapeutics, as well as solutions that include reagents, instruments, software and consumables. The Agilent CrossLab segment includes startup, operational, training and compliance support, software as a service, and asset management and consultative services. The company was founded in May 1999 and is headquartered in Santa Clara, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Agilent Technologies posts strong Q1 earnings, eyes PFAS testing and CRISPR expansion

Agilent Technologies delivered robust Q1 results, raised full-year guidance, and remains confident in its growth drivers. Despite challenges in the genomics market and uncertainties ahead, the company is strategically positioned to capitalize on opportunities and drive continued success.

Agilent reports strong Q2 earnings but revises down second-half forecast

Agilent Technologies delivered strong Q2 results but revised down second-half forecasts due to economic uncertainties. The company remains focused on driving margin expansion, cost efficiencies, and customer service excellence. Challenges from macroeconomic factors and market dynamics are being addressed with a strategic outlook for long-term growth.

Agilent Technologies faces China revenue challenges but eyes growth opportunities

Agilent Technologies faces revenue challenges in China but sees growth opportunities in companion diagnostics and liquid biopsy markets. The company remains confident in its ability to drive earnings growth despite recent setbacks.

Agilent reports mixed Q4 results, eyes steady recovery in 2024

Agilent Technologies reported mixed Q4 results with revenue decline but exceeded EPS guidance. While facing challenges in China and certain segments, the company anticipates slow but steady recovery for FY 2024. Agilent is focusing on cost-saving measures, pricing trends, and investments in growth areas like genomics and environmental solutions.

Agilent reports Q1 revenue decline, eyes global growth opportunities

Agilent Technologies' Q1 performance showed revenue decline but with strengths in certain segments like ACG and consumables. Challenges include revenue declines in DGG and LSAG impacting margins. Opportunities lie in global growth prospects and potential market surprises.

Agilent Technologies faces revenue decline but eyes growth opportunities ahead

Agilent Technologies navigated a challenging market in Q2 2024 with revenue declines across all end markets. The company remains focused on customer-centric strategies, cost optimization, and growth investments while addressing visibility challenges and exploring opportunities in high-growth segments.

Agilent reports Q3 earnings beat, eyes growth through acquisitions

Agilent Technologies delivered a solid performance in Q3 2024, exceeding earnings per share guidance and raising revenue and EPS midpoint guidance.
While facing revenue decline, the company's strategic investments and acquisitions signal a focus on growth and innovation.
Challenges include market dynamics and integration risks, but opportunities exist in leveraging digital initiatives and financial strength for future growth.

Agilent Technologies reports robust Q4 performance and outlines growth strategies

Agilent Technologies' Q4 2024 earnings call highlighted strong financial performance, strategic acquisitions, and a focus on margin expansion for sustainable growth.
Despite regional challenges and market uncertainties, the company remains optimistic about future prospects and is committed to driving EPS growth.
With a new market-focused approach and ongoing transformation initiatives, Agilent is well-positioned to capitalize on opportunities and navigate potential challenges in FY 2025.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Agilent Technologies (A) closed the most recent trading day at $159.81, moving -0.7% from the previous trading session.

Agilent Technologies (A) Dips More Than Broader Markets: What You Should Know

SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #Agilent--Agilent has named John Palma vice president of Medical Affairs.

Agilent Names John Palma to Lead Global Medical Affairs Organization

Agilent (A) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why the Earnings Surprise Streak Could Continue for Agilent (A)

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) announced today the new Agilent 6560C Ion Mobility LC/Q-TOF, enhancements to the VWorks automation software suite, and new AssayMAP large capacity cartridges. These solutions will be on show at the American Society for Mass Spectrometry Conference (ASMS) which is being held October 31 - November 4, 2021, in Philadelphia, PA. These products improve the analysis of proteins and peptides to speed up the development of new pr

Agilent Announces New Ion Mobility LC/Q-TOF and Enhanced Solutions for Biotherapeutics at ASMS 2021

Invesco QQQ

Here are trading recommendations for this coming strong week.

Stocks This Week: Buy ProShares Ultra QQQ And Agilent Technologies

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that its PD-L1 IHC 22C3 pharmDx assay is now labelled for use in TNBC in the European Union. PD-L1 expression is a critical biomarker for response to anti-PD-1 therapies such as KEYTRUDA® (pembrolizumab), an anti-PD-1 therapy manufactured by Merck (known as MSD outside the United States and Canada). The expanded use of PD-L1 IHC 22C3 pharmDx strengthens the ability of pathologists to identify patients who

Agilent Companion Diagnostic Expands CE-IVD Mark in Europe to Include Triple-Negative Breast Cancer (TNBC)

SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #Agilent--Agilent to webcast fourth quarter fiscal year 2021 financial results Monday, November 22.

Agilent to Webcast Fourth-Quarter Fiscal Year 2021 Financial Results Presentation

SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #Agilent--Agilent Technologies, Inc. (NYSE: A) today announced its commitment to achieve net-zero greenhouse gas emissions no later than 2050. The commitment adds to the global effort by governments, corporations, and other institutions to limit warming of the climate to 1.5°C above pre-industrial levels, a goal of the 2015 Paris Agreement on climate change. To ensure the company achieves its net-zero goals, Agilent has also committed to interim greenhouse gas reduct

Agilent Commits to Net-Zero Greenhouse Gas Emissions by 2050

Agilent Technologies Inc (NYSE: A) has committed to achieving net-zero greenhouse gas emissions no later than 2050. Agilent has also committed to interim greenhouse gas reduction targets.

ECLUSIVE: Agilent Commits to Net-Zero Greenhouse Gas Emissions By 2050

SANTA CLARA, Calif., Oct. 26, 2021 /PRNewswire/ -- Agilent Technologies Inc. (NYSE: A) announced today that it has undertaken the highest sponsorship level of My Green Lab —Transformative Level—as the first institution to do so.

Agilent Announced as My Green Lab's First 'Transformative Level' Sponsor and First Sponsor of the My Green Lab Certification Program

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced it has received CE-IVD mark approval for the PD-L1 IHC 28-8 pharmDx to guide options for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastroesophageal junction, or esophageal cancers. Gastric (stomach) cancer is the fifth most common cancer and the fourth leading cause of cancer death worldwide, with over 1,000,000 new cases and approximately 770,000 deaths

Agilent PD-L1 IHC 28-8 pharmDx Receives CE-IVD Mark as a Companion Diagnostic Test in Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

Bank of America

Citigroup

Goldman Sachs

iShares Core S&P 500 ETF

iShares S&P 500 Growth ETF

J.B. Hunt Transport Services

Invesco S&P 500 Pure Growth ETF

SPDR Portfolio S&P 500 ETF

SPDR S&P 500 ETF Trust

SPDR Portfolio S&P 500 Growth ETF

Vanguard S&P 500 ETF

Vanguard S&P 500 Growth ETF

Invesco S&P 500 Top 50 ETF

The rounds of upbeat earnings has set the stage for the S&P 500 Index to hit new highs as more Q3 earnings unfold.

ETFs to Ride on a Solid Start to Q3 Earnings

Air Products and Chemicals

Enphase Energy

Freeport-McMoRan

Generac Holdings

The S&P 500 Index wrapped up its best week since July, climbing 1.8% on encouraging quarterly earnings releases from several companies

5 Best Performing Stocks of the S&P 500 ETF Last Week

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced its Ki-67 IHC MIB-1 pharmDx (Dako Omnis) is now FDA approved as an aid in identifying patients with early breast cancer (EBC) at high risk of disease recurrence, for whom adjuvant treatment with Verzenio® (abemaciclib) in combination with endocrine therapy is being considered. This is the first IHC assay measuring Ki-67 expression to receive FDA approval in the context of treatment with Verzenio and was de

Agilent Receives FDA Companion Diagnostic Approval for Ki-67 IHC MIB-1 pharmDx in High-Risk Early Breast Cancer

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced Professor Bernhard Lendl has been selected to receive a prestigious Agilent Thought Leader Award. Highly renowned in the field of vibrational spectroscopy, Dr. Lendl is a professor at the TU Wien (Vienna) and head of the working group on Process Analysis & Vibrational Spectroscopy at the institution. Professor Lendl's work focuses on adapting powerful spectroscopic techniques and unique combinations of

Agilent Announces Thought Leader Award to Bernhard Lendl at the TU Wien (Vienna)

Accenture Plc

Automatic Data Processing

Federal Agricultural

Albemarle

Allstate

Andersons

Algonquin Power & Utilities

Alexandria Real Estate Equities

Artesian Resources

Atrion

Broadcom

Axis Capital

Brookfield Asset Management

BancFirst

Becton, Dickinson and Co.

Franklin Resources

Brookfield Renewable Partners

Brookfield Infrastructure Partners L.P.

Bank of South Carolina

Bristol-Myers

Cardinal Health

C&F Financial

C.H. Robinson Worldwide

A weekly summary of dividend activity for Dividend Champions and Contenders.

Dividend Champion And Contender Highlights: Week Of September 26

SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #Agilent--Pfizer executive Dr. Mikael Dolsten appointed to Agilent board of directors.

Dr. Mikael Dolsten Named to Agilent Board of Directors

SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #Agilent--Agilent announces dividend.

Agilent Announces Cash Dividend of 19.4 Cents per Share

American Water Works

Invesco S&P Global Water Index ETF

Danaher

Ecolab

Ferguson Enterprises Inc

First Trust Water ETF

Invesco

Invesco Water Resources ETF

Invesco Global Water ETF

Pentair

Roper Technologies

Veolia Environnement SA

Waters

Xylem

An in-depth look at the leading water ETFs in the U.S stock market.

Investing in Water ETFs

Agilent (A) reported earnings 30 days ago. What's next for the stock?

Agilent (A) Up 6.6% Since Last Earnings Report: Can It Continue?

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced Dr. David R. Liu has been selected to receive a prestigious Agilent Thought Leader Award. A prominent researcher in the field of genome editing, Dr. Liu is Professor and Director of the Merkin Institute of Transformative Technologies in Healthcare, Vice-Chair of the Faculty at the Broad Institute of MIT and Harvard, Professor of Natural Sciences and Professor of Chemistry and Chemical Biology at Harvard Un

Agilent Announces Thought Leader Award to David R. Liu at the Broad Institute

Agilent (A) signs an agreement with Visiopharm to globally distribute their pathology solutions.

Agilent (A), Visiopharm Unite for Supply of Pathology Solutions

News for Agilent Technologies Stock (A)